On p.10 of today’s presentation, some drugs with potential for TPM injectable reformulation are listed along with an indication of their relative US market opportunities.
Clopidogrel is identified as having a more sizeable market opportunity than either daptomycin or propofol, so I think it’s a fair guess that this might be one of the injectables that POH has been working on.
Here’s a brief rundown on clopidogrel.
Brand Name: Plavix
Market: Before patent expiry in 2012, Plavix was the world’s second highest selling drug, grossing over US$9bn in sales in 2010. There are now over a dozen approved Plavix generics. To date, all approved clopidogrel products are oral dosage.
Indications: Blood thinner. Used to prevent heart attacks and strokes in persons with heart disease (recent heart attack, recent stroke, or blood circulation disease). Also used with aspirin to treat new/worsening chest pain (new heart attack, unstable angina) and to keep blood vessels open and prevent blood clots after certain procedures (such as cardiac stent).
Mechanism of Action: Works by blocking certain blood cells called platelets and prevents them from forming harmful blood clots.
Currently approved dosing regimen: Loading dose of 300mg followed by a 75 mg once daily dose.
Limitations of oral dosage form: Bioavailability through intestinal absorption is ~ 50%. Initial high dose needed to reach effective drug level in blood. Takes several hours to reach effective drug levels in blood. Bleeding.
Hindrance to injectable formulation: Inherent chemical instability and poor solubility of clopidogrel.
Potential benefits of injectable formulation: Faster onset of action, vital in life-threatening emergency settings. Suitability for patients who are unable to take oral medications. Possible benefit for the significant proportion of patients who are nonresponders to orally administered clopidogrel.
https://www.medicinenet.com/clopidogrel-oral/article.htm
https://www.health.harvard.edu/blog/wallets-rejoice-as-plavix-goes-generic-201205214727
https://www.omicsonline.org/compara...e-dose-administration-jbb.1000029.php?aid=614
https://www.jscimedcentral.com/Pharmacology/pharmacology-3-1039.pdf
- Forums
- ASX - By Stock
- AVE
- Ann: Phospahgenics CEO Roadshow Presentation
Ann: Phospahgenics CEO Roadshow Presentation, page-10
-
- There are more pages in this discussion • 69 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVE (ASX) to my watchlist
|
|||||
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $9.507M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
48 | 86877619 | 0.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.3¢ | 60020911 | 20 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
48 | 86877619 | 0.002 |
22 | 69095508 | 0.001 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.003 | 60020911 | 20 |
0.004 | 17122582 | 17 |
0.005 | 22833333 | 10 |
0.006 | 19255067 | 9 |
0.007 | 5722471 | 6 |
Last trade - 16.12pm 21/08/2024 (20 minute delay) ? |
Featured News
AVE (ASX) Chart |
Day chart unavailable